Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

F. Haynes, Barton; B. Gilbert, Peter; Juliana McElrath, M.; Zolla‐Pazner, Susan; D. Tomaras, Georgia; Munir Alam, S.; T. Evans, David; C. Montefiori, David; Karnasuta, Chitraporn; Sutthent, Ruengpueng; Liao, Hua-Xin; L. DeVico, Anthony; K. Lewis, George; Williams, Constance; Pinter, Abraham; Fong, Youyi; Janes, Holly; C. deCamp, Allan; Huang, Yunda; Rao, Mangala; Billings, Erik; Karasavvas, Nicos; L. Robb, Merlin; Ngauy, Viseth; de Souza, Mark; Paris, Robert; Ferrari, Guido; T. Bailer, Robert; A. Soderberg, Kelly; Andrews, Charla; W. Berman, Phillip; Frahm, Nicole; C. De Rosa, Stephen; D. Alpert, Michael; L. Yates, Nicole; Shen, Xiaoying; A. Koup, Richard; Pitisuttithum, Punnee; Kaewkungwal, Jaranit; Nitayaphan, Sorachai; Rerks‐Ngarm, Supachai; L. Michael, Nelson; H. Kim, Jérôme

doi:10.1056/nejmoa1113425

Public

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Published in New England Journal of Medicine • Apr 4, 2012

Authors:

Barton F. Haynes

Peter B. Gilbert

M. Juliana McElrath

Abstract

BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood ...

Subject

Medicine

Immune system

Human immunodeficiency virus (HIV)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!